Your session is about to expire
← Back to Search
Rucaparib Maintenance Therapy for Endometrial Cancer
Study Summary
This trial will test if Rucaparib can help shrink endometrial cancer that has come back or spread after 1-2 other treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have serious heart conditions like recent heart attacks or unstable heart disease.I have significant liver disease or high liver enzyme levels.I am a woman aged between 18 and 89.I have a condition that affects how my body absorbs pills.My doctor expects I have less than 6 months to live.I have cancer that has spread to my brain.I am a woman able to have children but choose not to use birth control.I haven't had minor surgery in the last 2 weeks or major surgery in the last 4 weeks.My condition is advanced (Stage III/IV) or recurrent endometrial cancer.I completed radiation therapy on my pelvis or spine over 4 weeks ago.My cancer did not improve after my last chemotherapy.I have not had a stroke or mini-stroke in the last 3 months.It's been 4-8 weeks since my last cancer treatment.I can take care of myself and am up and about more than half of my waking hours.I have a history of a significant chronic disease like HIV/AIDS or hepatitis C.I completed 4 to 8 cycles of my first chemotherapy regimen.I have had 1 or 2 previous cancer treatments, including chemotherapy.I have not had cancer, other than endometrial or non-serious skin cancers, in the last 2 years.
- Group 1: Active Ingredient
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has a similar undertaking been attempted before?
"Since 2015, Active Ingredient has been intensely studied. It was first tested in a trial backed by Clovis Oncology, Inc., which included 924 participants and ultimately led to the drug's Phase 2 approval. Currently, 34 distinct experiments are being conducted across 831 cities located inside of 34 different countries."
Is this research endeavor currently recruiting participants?
"This clinical trial, which was initially posted on March 6th 2019 and recently revised on June 16th 2022 is currently recruiting participants according to information housed on clinicaltrials.gov."
Who can partake in the evaluation of this medical experiment?
"This clinical trial is open to 138 participants, between ages 18 and 89, who have metastatic endometrial cancer. In addition, in order to be considered for the study they must also meet a series of conditions such as having undergone at least one prior chemotherapy regimen with no more than two cytotoxic regimens (including hormonal therapy), completion of radiation if applicable within 8 weeks before initiation of drug, ECOG performance status 0-2 , ANC > or = 1500 cells/microliters and being a female aged 18-89 willing to comply with all study procedures.."
Is eligibility for this research study restricted to individuals under the age of 35?
"The requirements for participation in this clinical trial necessitate that the potential patient is between 18 and 89 years old. This study has a total of 19 child participants, while 310 elderly individuals are enrolled."
How many individuals are included in the research cohort?
"Affirmative. Clinicaltrials.gov displays that this medical experiment, which was initiated on March 6th 2019, is currently enrolling patients. 138 subjects must be enlisted from one particular hospital site."
Has the Active Ingredient gained regulatory clearance from the FDA?
"Our experts at Power assessed the safety of Active Ingredient to be a 2, due to its standing as a Phase 2 trial, which implies limited data on efficacy and some evidence on safety."
Share this study with friends
Copy Link
Messenger